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Increased vascularization of shoulder regions of
carotid atherosclerotic plaques from patients
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Fredrik J. Olson, PhD,a Sofia Strömberg, MD,a,b Ola Hjelmgren, MD,a,c Josefin Kjelldahl, BS,a
Björn Fagerberg, MD, PhD,a and Göran M. L. Bergström, MD, PhD,a,c Gothenburg, Sweden
Objective: Increased vascularization is considered an important contributing factor for plaque vulnerability. Microvascular
proliferative disease in patients with diabetes results in renal damage and visual loss.We assessed the hypothesis that vascularization
in carotid atherosclerotic tissue is increased in diabetic patients, especially in the critical shoulder regions of the plaque.
Methods: Carotid endarterectomy specimens, clinical data, and blood samples were collected from patients with symp-
tomatic carotid artery stenosis (median 85 days after clinical event) and pharmacologic treatment for diabetes (n  26)
or no diabetes (n  85). Plaques were fixed in formalin and transverse tissue sections prepared. Histopathology and
immunohistochemistry were performed for detection of endothelial cells (anti-CD34), macrophages (anti-CD68),
vascular endothelial growth factor (VEGF), and its receptor (VEGFR-2). Neovascularization was assessed as CD34
neovessel density in the entire section area and by the presence or absence of CD34 vessels in the shoulder and cap
regions of the plaques.
Results: The patient groups did not differ significantly in neovascularization in the entire transverse sections (2.0 vs 2.1
vessels/mm2; P  .61) or in the fibrous cap (52% of the patients in both groups; P  .95). Neovascularization of the
plaque shoulder regions was observed in 52% of the diabetic patients and in 26% of the nondiabetic patients (P  .028).
VEGF-stained areas were similar in the two patient groups (0.4% and 0.2% of shoulder area; P  .61). Patients with
diabetes had more VEGFR-2 (1.0% vs 0.2% of shoulder area; P< .016) and less CD68 staining (0.4% vs 3.6% of shoulder
area; P < .008). Time from clinical event to surgery was positively associated with neovascularization of the plaque
shoulder regions (<90 days, 18% of patients; >90 days, 50% of patients; P  .002), independently of diabetes status.
Conclusions: Diabetes was associated with increased vascularization of the shoulder regions in patients with symptomatic
carotid atherosclerotic plaques. This was accompanied by increased expression of VEGFR-2. The increased vasculariza-
tion of the plaque shoulder regions may help explain why patients with diabetes are at increased risk of atherosclerotic
complications. ( J Vasc Surg 2011;54:1324-31.)
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SClinical cardiovascular disease, such as ischemic stroke
and myocardial infarction, is often preceded by the rupture
of an atherosclerotic plaque in the vessel wall. Observa-
tional studies suggest that plaque vascularization may be a
risk factor for such cardiovascular complications. Cross-
sectional studies of plaque tissue from human carotid,1
coronary,2 and aortic3 atherosclerosis have shown that
vascularization is increased in clinically symptomatic com-
pared with asymptomatic atherosclerotic plaques. Further-
more, an association of histologic features of plaque insta-
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1324ility and increased vascularization is frequently reported.4
hese reports, however, are cross-sectional observational
tudies that provide no data on causality.
Evidence supporting plaque vascularization as a key
omponent in the development of future symptomatic
therosclerosis was recently found in the large Athero-
xpress study of carotid endarterectomy (CEA) specimens,
here the only aspects of plaque histology that could
redict future cardiovascular events were vascularization
nd intraplaque hemorrhage.5 The study by Hellings et al5
rovided the first evidence that plaque vascularization is not
ust a coincidental finding in symptomatic plaques but
redicts future cardiovascular events. Most newly formed
essels in atherosclerotic tissue are found in the important
houlder regions of the plaque,6 close to both the lipid core
nd the blood lumen.
Diabetes is associated with a more rapid progression of
therosclerosis as well as with increased frequency of ath-
rosclerotic complications.7,8 The exact mechanism medi-
ting this increased risk is not fully understood. A frequent
omplication of diabetes is microvascular proliferation that
esults in renal damage and visual impairment.9 This angi-
pathy may also occur in plaque tissue, resulting in the
roliferation of immature and fragile intraplaque vessels.7
tudies addressing this issue are scarce,10,11 however, and
o studies have focused on plaque shoulder vascularization
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Volume 54, Number 5 Olson et al 1325in diabetes and its associations with inflammation and
vascular endothelial growth factor (VEGF) and its receptor
(VEGFR-2).
Accordingly, we hypothesized that diabetic patients
have carotid atherosclerotic plaques with increased vascu-
larization, particularly in the shoulder regions of the
plaque. We tested this hypothesis by performing a cross-
sectional study of a series of carotid plaques obtained from
symptomatic patients undergoing CEA. Our aim was also
to clarify the relationship between diabetes and neovascu-
larization in the shoulder regions of the plaque, taking into
account such factors as inflammatory cell infiltration,
VEGF and VEGFR-2 expression, type of clinical symptoms
qualifying the patient for CEA, and the time passed from
the clinical event to surgery.
MATERIALS AND METHODS
Study population. Study approval was obtained from
the Regional Ethics Committee, and all patients gave in-
formed consent to participate. The study sample consisted
of symptomatic carotid atherosclerotic plaques obtained
from the Gothenburg and Umeå Vascular Study Group
biobank of patients who underwent CEA at the Sahlgren-
ska University Hospital in Gothenburg, Sweden. Criteria
Table I. Characteristics of the study population divided in
patients without diabetes
Characteristica No diab
Demographics
Females, n (%) 27 (
Age, years 68 (
Smokersc 33 (
Qualifying event
Type of cerebrovascular event
Amaurosis fugax 21 (
Transient ischemic attack 21 (
Minor ischemic stroke 43 (
Time: Clinical event to CEA,
days
82 (
Concomitant disease
Hypertension 52 (
Angina 14 (
Myocardial infarction 18 (
Medication
Statins 63 (
ARB or ACEI 31 (
Antithrombotic 79 (
Blood chemistry concentrations
hsCRP, mg/L 1.79 (
ApoB, g/L 1.07 (
ApoA1, g/L 1.41 (
ApoB/ApoA1 0.77 (
Triglyceride, mmol/L 1.58 (
VEGF, pg/mL 133 (
ACE, Angiotensin-converting enzyme inhibitor; Apo, apolipoprotein; AR
sensitive C-reactive protein; VEGF, vascular endothelial growth factor.
aContinuous data are presented as median (interquartile range) and categor
bStatistics used are Mann-Whitney U or 2 tests.
cSmoking 1 year preceding the clinical event.
dFrom 2 test performed on a contingency table including all three types ofqualifying for CEA were minor ischemic stroke, transient tschemic attack (TIA), or amaurosis fugax (AFX), and a
igh-grade carotid stenosis (70% determined with the
uropean Carotid Surgery Trial) method.12 The study
valuated a series of 120 consecutively collected plaques.
hree patients underwent CEA on both carotid arteries,
nd only the first operated plaque was included.
Patients with pharmacologic treatment of diabetes ver-
fied in medical records were classified as having diabetes
n  26). The study excluded nine patients with diet-
ontrolled diabetes or with ambiguous diabetes status. The
emaining 85 patients were classified as nondiabetic. Of
atients with diabetes, 18 were prescribed oral antidiabetic
reatment, five received insulin treatment, and three re-
eived a combination of both.
Clinical data and blood chemistry results were obtained
hrough patient questionnaires and medical records (Table
). There were no significant differences between the pa-
ient groups. The time between the clinical event and CEA
aried considerably, and in 12 patients, it was 6 months.
Tissue processing. Carotid plaques obtained during
EA were fixed in formalin immediately after surgical
emoval and were divided transversely at the point of the
ow divider in the bifurcation. Approximately 3-mm-thick
issue blocks were prepared and embedded in paraffin. One
tients with pharmacologically treated diabetes and
n  85) Diabetes (n  26) Pb
5 (19) .16
5) 72 (64-76) .23
8 (31) .50
.54d
4 (15)
6 (23)
16 (62)
15) 89 (43-145) .59
21 (81) .10
5 (19) .77
3 (12) .39
16 (62) .32
12 (46) .38
21 (81) .23
-2.90) 1.33 (0.97-2.77) .61
-1.27) 0.98 (0.83-1.12) .08
-1.57) 1.29 (1.18-1.49) .14
-0.95) 0.74 (0.61-0.85) .37
-2.46) 2.15 (1.54-2.39) .18
225) 157 (101-228) .94
giotensin receptor blocker; CEA, carotid endarterectomy; hsCRP, high-
as number (%).
rovascular events.to pa
etes (
32)
61-7
39)
25)
25)
51)
46-1
61)
16)
21)
74)
36)
93)
0.86
0.90
1.26
0.62
1.35
109-
B, an
ic dataissue block per patient was studied. The specimens were
m
a
C
d
u
i
G
s
t
b
A
i
d
n
c
c
m
o
o
w
o
C
g
u
v
M
t
s
c
R
t
n
p
T
p
m
r
m
P
s
t
w
t
i
n
n
h
v
(
m
w
JOURNAL OF VASCULAR SURGERY
November 20111326 Olson et alanatomically located in the internal carotid artery, adjacent
to the carotid bifurcation (for details see the Appendix,
online only). Results from a previous study showed that in
about 65% of plaques, this represents localization that is
close to the level of maximum stenosis.13
Serial transverse 4-m sections were prepared from the
paraffin blocks for histopathologic classification, histologic
staining, and immunohistochemical analysis. Histologic
analyses were performed on the entire transverse sections.
For a more detailed histologic assessment, we also identi-
fied the shoulder and cap regions of the plaque.
Definition of shoulder region and cap. Shoulder
regions were defined as the tissue adjacent to the outer
border of the lipid core down to the vessel lumen, and the
fibrous cap was defined as the tissue between the lipid core
and vessel lumen restricted by the shoulder regions (sche-
matic illustration and examples are given in the Appendix,
online only). The studied tissue sections contained one
(n  63), two (n  15), or three (n  4) lipid cores per
section. Two shoulder regions were defined for each ne-
crotic core, and in plaques with more than one necrotic
core, shoulder regions were defined for each core. All intact
shoulder regions were included in the analyses for each
section, and the combined result from all shoulder regions
in the section was given.
The analysis excluded individual shoulder regions of
tissue sections that were damaged and resulted in destroyed
shoulder regions. All histologic analyses and decisions on
exclusion of cap and shoulder regions were performed by
one author (J.K.), who was blinded for patient characteris-
tics and diabetes status. Owing to damaged tissue sections,
no data from the histologic analyses of cap and shoulder
regions could be obtained for five patients with diabetes
and 24 without diabetes, but the exclusion of these 29
patients did not introduce any significant differences be-
tween the patient groups, except in serum triglyceride
concentration, for which the tendency seen in Table I, with
slightly higher triglyceride levels in patients with diabetes,
now reached statistical significance (data not shown). Com-
pared with the included tissue sections, the excluded tissue
sections were more often classified as American Heart As-
sociation (AHA)13 classification 3 or 5 than AHA 4 or 6
(P  .05). This could possibly be due to poorer stability
during processing associated with more calcified areas.
Histopathologic classification, histologic staining,
and immunohistochemical analysis. Histologic staining
and histopathologic classification, including the AHA clas-
sification, were performed as described previously,13 using
histopathologic definitions from Lovett et al.14 Pretreat-
ment of sections are described in the Appendix (online
only). Immunohistochemical staining was done with
mouse monoclonal antibodies against CD34 as an endo-
thelial cell marker (1:25 dilution; DAKO, Glostrup, Den-
mark), VEGF (1:1000 dilution; Serotec, Oxford, UK), and
VEGFR-2 (1:100 dilution; Serotec). Immune complexes
were visualized using the MACH3 Mouse-Probe Alk Phos
Polymer Kit (BioCare Medical, Concord, Calif) and the
Vulcan Fast Red Chromogen kit (BioCare Medical). Pri- aary antibody incubation was performed in room temper-
ture for 1 hour.
Immunohistochemical staining of macrophages (anti-
D68) and smooth muscle cells (anti-SMA) was done as
escribed previously.13 Stained sections were digitalized
sing a ZeissMirax Scanner (Zeiss, Jena, Germany). Digital
mages were analyzed using the BioPix software (BioPix AB,
othenburg, Sweden). The extent of immunohistochemical
taining is expressed as a percentage of the stained area of the
otal section area or of the total shoulder area, where applica-
le. Settings for thresholds and intensities are described in the
ppendix (online only). CD34 vessel density was analyzed
n a computer (original magnification40).
Neovascularization was assessed as CD34 neovessel
ensity on the entire tissue sections and expressed as the
umber of vessels per total section area, excluding the lipid
ore. In the analyses of shoulder and cap regions, neovas-
ularization was assessed both as a continuous density
easure and also dichotomously as the presence or absence
f any CD34 neovessels. In plaques that had more than
ne core, the presence of one vascularized shoulder or cap
as enough to be considered as vascularized in the dichot-
mous analyses.
Statistical analysis. SPSS 18.0 software (SPSS Inc,
hicago, Ill) was used for statistical analyses. Results are
iven as median and interquartile range (IQR) for contin-
ous variables, or as count and percentage for categoric
ariables. Statistical significance was assessed using the
ann-Whitney U test or the 2 test. Independent associa-
ions were assessed with logistic regression analysis. Two-
ided P values  .05 were considered statistically signifi-
ant.
ESULTS
Plaque morphology. Morphologic and immunohis-
ochemical analyses of entire transverse tissue sections did
ot reveal any statistically significant differences between
laques from patients with and without diabetes (Table II).
he median areas of the cap regions were, respectively for
atients with and without diabetes, 2.11 mm2 (IQR, 1.62
m2) and 2.02 mm2 (IQR, 2.54 mm2; P  .94), and the
espective median areas of the shoulder regions were 0.25
m2 (IQR, 0.25 mm2) and 0.26 mm2 (IQR 0.32 mm2;
 .42).
Vessel density and neovascularization. We found no
ignificant difference in the vessel density measured over
he entire tissue sections between plaques from patients
ith and without diabetes (Table II) and no difference in
he density (P .92) or frequency of CD34 neovascular-
zation in the fibrous cap (52% of diabetic patients vs 52% of
ondiabetic patients; P  .95). By contrast, density of
eovascularization in the plaque shoulder regions was
igher in patients with diabetes (P  .034, Fig 1). When
ascular density was expressed as a frequency distribution
Fig 2), the distribution was skewed toward zero, most
arkedly in the nondiabetic group (P .005). In addition,
hen vascularization was analyzed as a dichotomized vari-
ble (no vascularization vs any vascularization), it was ob-
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Volume 54, Number 5 Olson et al 1327served in 52% of patients with diabetes vs in 26% in those
without diabetes (P  .028). Plaques from patients with
AFX often have a milder phenotype than plaques from
patients with stroke or TIA.15 An analysis that excluded
patients with AFX showed even more marked differences in
shoulder vascularization between patients with and without
diabetes (61% vs 28%; P  .015).
Expression of growth factors and markers of inflam-
mation in the shoulder regions. Immunohistochemical
staining of plaque shoulder regions revealed no difference in
the relative amount of VEGF between the patient groups (Fig
3,A). In contrast to this finding, its receptor, VEGFR-2, was
significantly more abundant in the shoulder regions of
plaques from patients with diabetes than in patients
without diabetes (Fig 3, B) and was more abundant in
vascularized plaque shoulders than in nonvascularized
plaque shoulders (Fig 3, C).
Immunohistochemical staining of CD68 macro-
phages was analyzed as a measure of inflammation, and
lower levels of inflammation were found in the shoulder
regions of plaques from patients with diabetes than in
patients without diabetes (Fig 3, D). The level of inflam-
mation by CD68-stained area was 3.5% (IQR 9.6) in vas-
cularized shoulder regions vs 2.6% (IQR 7.4) in nonvascu-
Table II. Morphologic and immunohistochemical
characterization of cross-sectional tissue sections taken
from the internal carotid artery
Variablesa
No diabetes
(n  85)
Diabetes
(n  26) Pb
Morphology
Lipid core size,c % 27 (10-46) 35 (20-50) .29
Rupture of the
fibrous cap
41 (48) 11 (42) .56
Thrombus 32 (38) 7 (27) .30
Intraplaque
hemorrhage
47 (55) 15 (58) .81
Thin fibrous cap 65 (76) 18 (70) .38
AHA classification .35d
Type III 4 (5) 0 (0)
Type IV 24 (28) 7 (27)
Type V 12 (14) 7 (27)
Type VI 41 (48) 11 (42)
Immunohistochemistryc
CD68 macrophage
area, % 8.8 (3.2-17.3) 2.9 (1.2-10.9) .07
Smooth muscle cell
area, % 2.0 (0.4-5.5) 1.8 (0.6-5.1) .86
Collagen area, % 13.9 (8.3-21.7) 15.1 (7.3-26.0) .69
CD34 neovessel
density,d n/mm2 2.0 (0.6-4.0) 2.1 (0.3-6.7) .61
AHA, American Heart Association;
aContinuous data are presented as median (interquartile range) and cate-
goric as number (%).
bStatistics used are Mann-Whitney U or 2 tests.
cData are presented as % of the total area; neovessel density data as density in
the entire section.
dFrom 2 test performed on a contingency table, including all four present
AHA types.larized, which was not significantly different (P  .28). sShoulder region neovascularization. The time from
he clinical event to CEA varied between 6 and 253 days in
he study population and was positively associated with the
resence of CD34 vessels in the plaque shoulder regions.
eovascularized shoulder regions were found in plaques
rom eight of 44 patients (18%) who underwent CEA90
ays from the most recent clinical event, compared with
laques of 19 of 38 patients (50%) who underwent CEA
90 days after the most recent event (P  .002). The
igher occurrence of shoulder vascularization in patients
ith diabetes than in patients without diabetes was inde-
endent of the time between the clinical event and CEA,
ith an OR of 3.1 (95% CI, 1.0-9.5; P .041) for diabetes
s nondiabetes and an OR of 4.6 (95% CI, 1.6-12.8; P 
004) for a duration 90 days vs 90 days from the event
o surgery (Fig 4). Time from the clinical event to surgery
id not correlate with CD68, VEGF, or VEGFR-2 stain-
ng.
Data on histologic features of plaques are reported in
able II. A comparison of the different types of cerebrovas-
ular events showed vascularization was more common in
he plaque shoulders of patients with minor ischemic stroke
42%) than in TIA or AFX (22%) patients (P  .048). No
ifferences in shoulder vascularization were found between
atients with and without statin medication (P  .84).
ISCUSSION
In this study of carotid plaques from patients with
ymptomatic atherosclerotic disease, we showed that the
ig 1. Box plot shows the density of neovascularization in shoul-
er regions of plaques from patients with (DM) and without
non-DM) diabetes mellitus. Differences between the patient
roups were assessed with the Mann-Whitney U test. The top
order of the box shows the 75th percentile, the whisker shows the
ange of the data, and the horizontal line in the box shows the
edian.houlder regions had a higher density of vessels and were
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November 20111328 Olson et almore frequently vascularized in plaques from patients with
diabetes compared with patients without diabetes. Patients
with diabetes also had increased VEGFR-2 expression in
the plaque shoulder regions, whereas the expression of
macrophage markers was reduced. Furthermore, vascular-
ization increased with time between the clinical event and
surgery, independently of diabetes status, inflammation,
and VEGF/VEGFR-2 expression.
Despite its potential clinical significance, only a few
reports have been published on the vascularization of ca-
rotid plaques from patients with diabetes, and our analysis
provides novel information on possible disease mechanisms
in diabetes. Two smaller studies have reported increased
Fig 2. Histogram shows the frequency distribution (%) of neo-
vascularization density in the plaque shoulder regions in patients
with and without diabetes mellitus (non-DM). The number on top
of each bar indicates the exact number of plaques within each
frequency domain. The 2 test was used to assess the difference
between the plaques of patients with and without DM.vascularization in carotid16 and femoral11 plaques from hatients with diabetes. By contrast, a semiquantitative anal-
sis of vascularization in plaques from a large number of
atients failed to detect a difference between patients with
ormal glucose tolerance, impaired glucose tolerance, or
iabetes.10
Vascularization of plaque tissue is not uniform, how-
ver, and is often seen as microfocal accumulations of
essels in the shoulder regions,6 which could potentially
xplain the discrepancy in the results. In the present study,
e analyzed the shoulder and cap regions specifically and
ere able to show that the suggested difference in plaque
ascularization between patients with and without diabetes
as localized to the shoulder regions of the plaques.
The observed upregulated expression of VEGFR-2 in
he shoulder region of plaques in the diabetes group may
rovide a mechanistic background to our findings of in-
reased vascularization. The VEGF/VEGFR-2 system,
hich is the main regulator of physiologic and pathologic
ngiogenesis,17 is activated in many diseases involving vas-
ular proliferation, including atherosclerosis and diabetic
etinopathy.18 Although increased VEGF expression in
isease has been well documented,18 less is known about
he complex regulation of expression, stability, and activity
f VEGFR-2.17 One of the most powerful inducers of
EGFR-2 expression is hypoxia,17 and it is well known that
he interior of the plaque is hypoxic.19 Diabetes-associated
icrovascular disease may possibly result in an impaired
xygen delivery, but this hypothesis has not yet been ad-
ressed in any studies of plaque tissue.
Although the initiating step in plaque neovasculariza-
ion is most likely hypoxia, there is also an association with
nflammatory changes in the plaque,20 but the exact causal
elationship between inflammatory changes and neovascu-
arization is not yet known. The current study showed no
ssociation between the degree of inflammation and vascu-
arization in the plaques, and less inflammation was present
n the shoulder region of plaques from diabetic compared
ith nondiabetic patients. Indeed, increased inflammation
n plaques from patients with diabetes is not a consistent
nding in the literature. Similar numbers of CD3 lympho-
ytes and CD68 macrophages in diabetes and control
laques have been reported.10,21,22 However, two studies
n coronary plaques23,24 and one in carotid plaques25
howed an increased infiltration of macrophages in plaques
rom patients with diabetes. Even though we did not find
ny significant differences inmedication or blood chemistry
etween the patient groups, it is possible that a tighter
ontrol of vascular risk factors in patients with diabetes may
onfound the interpretation of our own and others’ data.
We found that the frequencyof vascularizedplaque shoul-
ers increased with longer times between the qualifying clin-
cal event and CEA, independently of diabetes status. This
uggests that increased vascularization is associated with heal-
ng of the plaque in the aftermath of a plaque rupture, in
nalogy with wound healing in other tissues.26 The time
etween the qualifying symptom and harvest of the plaque is
ot always reported, despite its known effects on plaque
istology.27,28 A prospective study by Hellings et al5 found
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Volume 54, Number 5 Olson et al 1329that increased vascularization was independently associated
with poor prognosis. However, information on the possible
effect of time between qualifying symptom and plaque harvest
was not included in the analyses but would have been inter-
esting in the light of the current findings. A mechanistic link
between vascularization, intraplaque hemorrhage, and the
clinical event has been proposed, and some support for this
hypothesis has been presented.29
A limitation of the current report is that we exclusively
studied symptomatic plaques. It would be interesting to see
if similar patterns were found in patients without previous
symptoms. It is difficult to generate large biobanks of tissue
with relevant clinical information. The sample size of this
study, which focuses on the subgroup of patients with
diabetes, was therefore relatively small and was further
Fig 3. Extent of immunohistochemical staining is shown
patients with (DM) and without (non-DM) diabetes mellitu
to the total shoulder area. The bordersof the box show the75
and the horizontal line in the box shows themedian.A,Vas
and non-DM patients. B, VEGF receptor-2 (VEGFR-2) s
staining is shown in vascularized and nonvascularized plaq
patients. The Mann-WhitneyU test was used to assess differeduced by the analysis of shoulder regions. We cannot rule cut that the small sample size introduced sampling and
election bias that may have affected our results.
Furthermore, it is becoming increasingly clear that the
orphology of the plaque differs depending on where the
issue section is taken in relation to the maximum steno-
is.13 It can be assumed that vascularization would also be
ffected. However, we did not have data on the exact
ocation of the maximum stenosis in all of our patients
ecause magnetic resonance angiography was only per-
ormed in a subset of patients. Instead, the tissue sections
ere taken from the proximal portion of the internal ca-
otid artery at a predefined distance from the flow divider
etween the external and internal carotid artery. From
revious experience, we know that in about 65% of patients,
he current approach results in selection of a tissue section
he shoulder regions of carotid atherosclerotic plaques in
e box plots show the areas stained with antibodies relative
d25th percentiles, thewhiskers shows the range of the data,
ndothelial growth factor (VEGF) staining is shown inDM
g is shown in DM and non-DM patients. C, VEGFR-2
ulders. D, CD68 staining is shown in DM and non-DM
s between the patient groups.in t
s. Th
th an
cular e
tainin
ue sholose to the level of maximum stenosis.13 Another limita-
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November 20111330 Olson et altion of the present study is the cross-sectional design, which
only allowed us to draw conclusions on association rather
than mechanisms.
CONCLUSIONS
Our findings of increased vascularization of carotid
plaque shoulder regions in patients with diabetes may have
clinical implications and help explain the increased risk of
atherosclerosis-related cardiovascular events seen in this
patient group. However, this is an observational study with
limited sample size and further studies of mechanisms
explaining the effect of diabetes on plaque vascularization
are needed.
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Methods
Pretreatment of sections. Before antibodies were ap-
plied, histologic sections were deparaffinized and pre-
treated with an antigen-retrieval reagent, DIWA Decloacer
(Biocare Medical, Concord, Calif). Endogen peroxidase
and nonspecific background staining were quenched using
two different blockers, PeroxAbolish and Background
Sniper, respectively (Biocare Medical).
Assessment of intensity and amount of staining.
Weak color intensity as a result of diffuse nonspecific stain-
ing in control sections stained using appropriate immuno-
globulin G controls or in control staining by omission of
primary antibodies was set as the threshold. This threshold
was subtracted from the color intensity detected in sections
stained using antibodies recognizing specific antigens. Sec-
tions were not counterstained. (Appendix Figs 1-5).tppendix Fig 1 (online only). A significant Spearman correla-
ion was found between vascular density in plaque shoulders and
he time since the last clinical event. This suggests that there is an
ssociation between the clinical event and increased vasculariza-
ion.
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 5 Olson et al 1331.e2Appendix Fig 2 (online only). A, Schematic illustration shows the location of the analyzed section in the plaque.
B-D, The arrow indicates from which side cross-sectional 4-m slices were taken for histology in examples of the tissue
sections with definition of shoulder and cap regions. C, Lipid core; F, fibrous cap; L, blood lumen; S, shoulder region.
JOURNAL OF VASCULAR SURGERY
November 20111331.e3 Olson et alAppendix Fig 3 (online only). Illustration shows a plaque that (A, B) scored positive for vascularization in the
shoulder region and a plaque that (C, D) scored negative for shoulder vascularization in (A, C) normal and (B, D)
high-magnification (original magnification 10) views. The arrows show CD34 cells in vessels in the (B) shoulder
area and on the (D) lumen of the vessel.
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 5 Olson et al 1331.e4Appendix Fig 4 (online only). Schematic illustration of immunohistochemical staining of (A, B) smooth muscle cells
(anti-SMA) and (C, D) macrophages (anti-CD68) in (A, C) normal and (B, D) high-magnification (original
magnification 10) views. Immune complexes were visualized using the LSAB System HRP Kit (Dako).
JOURNAL OF VASCULAR SURGERY
November 20111331.e5 Olson et alAppendix Fig 5 (online only). Schematic illustration shows immunohistochemical staining of (A, B) vascular
endothelial growth factor (VEGF) and (C, D) VEGF receptor 2 in (A, C) normal and (B, D) high-magnification
(original magnification 10) views. Immune complexes were visualized using the MACH3 Mouse-Probe Alk Phos
Polymer Kit and the Vulcan Fast Red Chromogen Kit (BioCare Medical).
